Replies to post #107686 on Biotech Values

[DewDiligence]

MRK has some problems. To wit:

• Boceprevir is looking more and more like a commercial dud with each passing day (#msg-54317080, #msg-56152791).

• Gardasil has turned out to be a tough sell (#msg-54120045).

• The Zetia/Vytorin franchise probably can’t be rejuvenated (#msg-26000935).

• The NDA for a Lipitor+Zetia combo pill got a Refusal-to-File Letter (#msg-43169725).

• Cordaptive is delayed until 2013—or later (#msg-30170058).

• GILD and GSK have Isentress in their crosshairs and could supplant it with qD integrase inhibitors (#msg-30900183, #msg-55878096).

• MRK has been oddly quiet lately about TRA, the purported antiplatelet blockbuster-in-waiting that MRK acquired from SGP.

• Singulair, MRK’s largest drug, goes off-patent in less than two years.

• I expect MRK to lose the Remicade/Simponi arbitration and thereby forfeit the ex-US rights to these drugs or have to pay JNJ a hefty concession (#msg-55521924).

Did I miss anything?